Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alimera Sciences Inc announces resubmission of ILUVIEN NDA to FDA


Thursday, 27 Mar 2014 07:00am EDT 

Alimera Sciences Inc:Resubmitted NDA for ILUVIEN to U.S. FDA.ILUVIEN is injected in back of patient's eye to a position that takes advantage of eye's natural fluid dynamics.Most frequently reported adverse drug reactions included cataract operation, cataract and increased ocular pressure.ILUVIEN received marketing authorizations in Austria, UK , Portugal, France, Germany and Spain and is commercially available in UK and Germany.ILUVIEN has not been approved for sale in US. 

Company Quote

5.61
-0.03 -0.53%
22 Aug 2014